SAB Biotherapeutics, Inc.
2301 E 60th St N
Sioux Falls
South Dakota
57104
United States
124 articles about SAB Biotherapeutics, Inc.
-
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
8/11/2021
SAB Biotherapeutics today announced the publication of data showing that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 infections, demonstrates effective and potent neutralization of multiple SARS-CoV-2 variants of concern, including the Delta and Lambda variants.
-
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
7/9/2021
SAB Biotherapeutics announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13 at 5:00 p.m. ET.
-
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
7/8/2021
Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern
-
SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza
6/29/2021
SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies, announced that the first participant has been dosed in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a human challenge study.
-
Money on the Move: June 16 – 22
6/23/2021
Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week. -
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases
6/22/2021
SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale, and Big Cypress Acquisition Corp., a blank check company focused on innovative biopharmaceutical firms, announced that they have entered into a definitive business combination agreement.
-
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.
-
SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021
6/14/2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high potency, fully-human polyclonal antibodies at scale, today announced that Eddie J. Sullivan, PhD, co-founder, president, CEO, will serve as an expert panelist during BIO Digital 2021.
-
SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs
6/10/2021
SAB Biotherapeutics (SAB), today announced the appointment of Carlos Carrillo, PhD, as senior vice president, regulatory affairs.
-
SAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
5/13/2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will participate in a fireside chat at the RBC Capital Markets 2021 Global Healthcare Conference on Thursday, May 20, 2021 at 11:30 a.m. ET.
-
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
4/21/2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that the first patient has been dosed in its Phase 2/3 study evaluating the safety and efficacy of SAB-185, a polyclonal antibody therapeutic candidate in non-hospitalized adults with mild to moderate COVID-19 as part of the NIH’s ACTIV-2 master protocol.
-
SAB Biotherapeutics Strengthens Senior Management Team with Appointment of Kipp Erickson, PhD as Chief Operating Officer
4/13/2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies, today announced that Kipp Erickson, PhD, has joined the company as Chief Operating Officer (COO).
-
BioSpace Movers & Shakers, Dec. 18
12/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19
8/21/2020
Phase 1b clinical trial will evaluate the safety and pharmacological activity of SAB-185 in COVID-19 patients Second study initiated this month testing SAB-185 for the treatment of COVID-19 SIOUX FALLS, S.D.--( BUSINESS WIRE )-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, today announced the dosing of the first patient in its Phase 1b
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
-
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19
8/11/2020
First participant dosed in Phase 1 study of SAB-185 for COVID-19 in healthy volunteers Phase 1b clinical trial evaluating the safety and pharmacological activity of SAB-185 in COVID-19 patients slated to start mid-August Novel proprietary technology platform leverages the native human immune response offering a differentiated high-potency therapeutic option to address virus mutations amidst ongoing pandemic
-
SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program
8/6/2020
SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program Funds clinical development and manufacturing of SAB-185, a therapeutic candidate for COVID-19, as well as increased production capacity for rapid response JPEO-CBRND is also providing additional direct funding for first-in-human clinical studies in continued collaboration with BARDA, which remain on track
-
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-176 for Seasonal Influenza
7/30/2020
SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors, today announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SAB-176 for the treatment of seasonal influenza. SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy desig
-
SAB Biotherapeutics Closes Series B Funding
7/17/2020
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced it has closed its Series B funding round at $14 million. New investor, global healthcare leader Merck, known as MSD outside the United States and Canada, was joined by South Dakota Equity Partners and several other foll